Decrease in intracellular Zn²⁺ level by propranolol : A model experiment using rat thymocytes Decrease in intracellular Zn^<2+> level by propranolol : A model experiment using rat thymocytes
Propranolol is a representative β-blocker used for the treatment of cardiovascular diseases. Because the useof propranolol expands for some clinical purposes that are not related to its β-blocking action, it is necessary tofurther examine cellular actions of propranolol. We revealed that propranolol decreased the intracellular Zn2+level in rat thymocytes by the use of cytometric technique with FluoZin-3, a fluorescent indicator of intracellularZn2+. Propranolol decreased the influx of extracellular Zn2+. However, the agent decreased the intracellularZn2+ level even in the presence of DTPA, a chelator of extracellular Zn2+. Thus, the decrease in intracellularZn2+ level by propranolol was not due to the decrease in Zn2+ influx by propranolol. Propranolol increased thecellular content of nonprotein thiol that was estimated by the use of 5-chloromethylfluorescein fluorescence, anindicator for non-proteinous thiol. Since non-proteinous thiols can make a complex with Zn2+, propranolol mayincrease the cellular content of nonprotein thiol, resulting in the decrease in intracellular Zn2+ level. Since theconcentrations of propranolol to affect both intracellular Zn2+ level and cellular content of nonprotein thiol arehigher than those reported under clinical conditions, it is difficult to emphasize clinical implications from presentresults.
徳島大学総合科学部自然科学研究 26, 11-16, 2012